The Government has approved a new form of fast-acting insulin to be listed on the Pharmaceutical Benefits Scheme (PBS) from October 1st.
The listing will be welcome news for the more than 15,000 Australians living with diabetes who were affected by the removal by the supplier of the products Fiasp and Fiasp FlexTouch (forms of fast-acting insulin aspart) from the PBS.
In March, the Government secured access to Fiasp and Fiasp FlexTouch for a further six months and has since negotiated with drug sponsor Novo Nordisk to list a new form of the fast-acting insulin aspart, Fiasp Penfill.
“Australians with type 1 diabetes can breathe a sigh of relief knowing they will continue to have affordable access to fast-acting insulin,” said Federal Health Minister, Mark Butler.
“We understand how important it is for people with type 1 diabetes to have access to a stable supply of products and medications to manage their illness.
Available under the same conditions as the previous PBS listing, Fiasp Penfill quickly reduces blood sugars and helps to minimise spikes after eating.
“Diabetes is a demanding and complicated condition that needs constant monitoring,” said Diabetes Australia Group CEO, Justine Cain.
“Australians living with diabetes need access to the best available insulins and medicines, at affordable prices, to have their best quality of life and reduce the impact of diabetes-related complications.”
